Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John T Poirier

Showing results (1-10 of 96) with videos related to

Pageof 10
Sort By:
Progress in Molecular Biology and Translational Science|November 19, 2017
CRISPR Libraries and ScreeningJohn T Poirier
Nature Reviews. Clinical Oncology|December 14, 2016
Small-cell lung cancer in 2016: Shining light on novel targets and therapiesCharles M Rudin, John T Poirier
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 28, 2017
Histone Code Aberrancies in Small Cell Lung CancerEric E Gardner, John T Poirier, Charles M Rudin
The FEBS Journal|June 3, 2016
Design, execution, and analysis of pooled in vitro CRISPR/Cas9 screensLinde A Miles, Ralph J Garippa, John T Poirier
Oncolytic Virotherapy|March 19, 2020
Virus-Receptor Interactions and Virus Neutralization: Insights for Oncolytic Virus DevelopmentNadishka Jayawardena, John T Poirier, Laura N Burga, et al.
Journal of Lipid Research|August 5, 2022
Generation of hepatoma cell lines deficient in microsomal triglyceride transfer proteinNarasimha Anaganti, Atrayee Chattopadhyay, John T Poirier, et al.
Oncolytic Virotherapy|November 23, 2019
Virus-Receptor Interactions: Structural Insights For Oncolytic Virus DevelopmentNadishka Jayawardena, Laura N Burga, John T Poirier, et al.
Plos One|June 13, 2015
Seneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for Use in Peptide-Prodrug TherapyLinde A Miles, W Nathaniel Brennen, Charles M Rudin, et al.
Plos One|August 20, 2015
Correction: Seneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for use in Peptide-Prodrug TherapyLinde A Miles, W Nathaniel Brennen, Charles M Rudin, et al.
Molecular Cancer Therapeutics|August 19, 2007
Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2-positive breast cancerJonathan D Mosley, John T Poirier, Darcie D Seachrist, et al.
Pageof 10

Showing results (1-10 of 96) with videos related to

Sort By:
Pageof 10
Progress in Molecular Biology and Translational Science|November 19, 2017
CRISPR Libraries and ScreeningJohn T Poirier
Nature Reviews. Clinical Oncology|December 14, 2016
Small-cell lung cancer in 2016: Shining light on novel targets and therapiesCharles M Rudin, John T Poirier
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 28, 2017
Histone Code Aberrancies in Small Cell Lung CancerEric E Gardner, John T Poirier, Charles M Rudin
The FEBS Journal|June 3, 2016
Design, execution, and analysis of pooled in vitro CRISPR/Cas9 screensLinde A Miles, Ralph J Garippa, John T Poirier
Oncolytic Virotherapy|March 19, 2020
Virus-Receptor Interactions and Virus Neutralization: Insights for Oncolytic Virus DevelopmentNadishka Jayawardena, John T Poirier, Laura N Burga, et al.
Journal of Lipid Research|August 5, 2022
Generation of hepatoma cell lines deficient in microsomal triglyceride transfer proteinNarasimha Anaganti, Atrayee Chattopadhyay, John T Poirier, et al.
Oncolytic Virotherapy|November 23, 2019
Virus-Receptor Interactions: Structural Insights For Oncolytic Virus DevelopmentNadishka Jayawardena, Laura N Burga, John T Poirier, et al.
Plos One|June 13, 2015
Seneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for Use in Peptide-Prodrug TherapyLinde A Miles, W Nathaniel Brennen, Charles M Rudin, et al.
Plos One|August 20, 2015
Correction: Seneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for use in Peptide-Prodrug TherapyLinde A Miles, W Nathaniel Brennen, Charles M Rudin, et al.
Molecular Cancer Therapeutics|August 19, 2007
Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2-positive breast cancerJonathan D Mosley, John T Poirier, Darcie D Seachrist, et al.
Pageof 10